Details

Autor(en) / Beteiligte

• ENGE, DANIEL
• SCHÄFER, MICHAL
• FUJIWARA, TAKASHI
• CLARK, ETHAN
• ENGLUND, ERIN
• SCALZO, REBECCA L.
• RAFFERTY, DEIRDRE
• SCHAUER, IRENE E.
• ABUSHAMAT, LAYLA
• WHIPPLE, MARY O.
• HUNTER, KENDALL S.
• NADEAU, KRISTEN J.
• REGENSTEINER, JUDITH G.
• BARKER, ALEX J.
• REUSCH, JANE

Titel

414-P: Effects of Obesity and Type 2 Diabetes on Cardiac Structure and Arterial Stiffness

Ist Teil von

• Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

Ort / Verlag

New York: American Diabetes Association

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• T2D is a global epidemic leading to excess cardiovascular (CV) mortality including heart failure (HF) . Strategies are emerging to prevent HF progression, so early detection is needed. We have identified preclinical cardiac dysfunction associated with central arterial stiffness and decreased cardiorespiratory fitness. We hypothesized that cardiac magnetic resonance (CMR) would identify changes in diabetes. Methods: Age and BMI-similar premenopausal women and men with (n=24) and without (n=30) uncomplicated T2D were studied. CMR for cardiac function, regionally resolved pulse wave velocity (PWV) via 2D phase-contrast MRI assessed proximal arterial stiffness, and carotid to femoral applanation tonometry PWV (C-F PWV) using SphygmoCor assessed global arterial stiffness. The vascular territories covered by SphygmoCor does not include the ascending aorta. Results: CMR showed significant changes consistent with cardiac dysfunction in T2D (Table 1) . PWV was significantly greater with T2D in the ascending and proximal descending aorta (p<0.05) . Subclinical diastolic cardiac dysfunction (EDVi) correlated with proximal PWV in T2D (p=0.046, r2=0.24) . C-F PWV did not differ between groups. Conclusions: CMR detects early arterial stiffening in people with uncomplicated T2D and mild cardiac dysfunction. These findings support the use of CMR for detecting central arterial stiffness and incipient CV complications. Disclosure D.Enge: None. M.O.Whipple: None. K.S.Hunter: None. K.J.Nadeau: None. J.G.Regensteiner: None. A.J.Barker: None. J.Reusch: Advisory Panel; Medtronic. M.Schäfer: None. T.Fujiwara: None. E.Clark: None. E.Englund: None. R.L.Scalzo: None. D.Rafferty: None. I.E.Schauer: None. L.Abushamat: None. Funding National Institutes of Health (CX001532) University of Colorado Denver (NCT03419195) National Institutes of Health (R01-DK-124344) National Institutes of Health (K25HL119608)